Vyant Bio, Inc.
VYNT
OTC PK
Weiss Ratings | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Unrated | |||
Risk Index | Unrated | |||
Risk Grade | U | |||
Reward Grade | U | |||
Rating Factors | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | Unrated | |||
Growth Index | Unrated | |||
Efficiency Index | Unrated | |||
Solvency Index | Unrated | |||
Total Return Index | Unrated | |||
Volatility Index | Unrated | |||
Beta / Standard Deviation | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.19 | |||
Price History | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 0.00% | |||
30-Day Total Return | 0.00% | |||
60-Day Total Return | 0.00% | |||
90-Day Total Return | 0.00% | |||
Year to Date Total Return | 0.00% | |||
1-Year Total Return | 0.00% | |||
2-Year Total Return | -61.21% | |||
3-Year Total Return | -96.57% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -3.00% | |||
52-Week Low % Change | 10.86% | |||
Price | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $0.20 | |||
52-Week Low Price | $0.18 | |||
52-Week Low Price (Date) | Apr 10, 2025 | |||
52-Week High Price (Date) | Apr 10, 2025 | |||
Valuation | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | -- | |||
Enterprise Value | -- | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -2.28 | |||
Earnings Per Share Growth | -70.02% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 3.09 | |||
Price/Book (Q) | 0.27 | |||
Enterprise Value/Revenue (TTM) | -2.17 | |||
Price | $0.19 | |||
Enterprise Value/EBITDA (TTM) | 0.06 | |||
Enterprise Value/EBIT | 0.06 | |||
Market Cap Category | -- | |||
Dividends and Shares | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 6.33M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 201 479 1357 | |||
Address | 2 Executive Campus Cherry Hill, NJ 08002 | |||
Website | www.vyantbio.com | |||
Country | United States | |||
Year Founded | -- | |||
Profitability | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -3,445.84% | |||
Profit Margin | -3,482.87% | |||
Management Effectiveness | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -51.76% | |||
Return on Equity | -- | |||
Income Statement | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 397.00K | |||
Total Revenue (TTM) | 397.00K | |||
Revenue Per Share | $0.06 | |||
Gross Profit (TTM) | -339.00K | |||
EBITDA (TTM) | -13.28M | |||
EBIT (TTM) | -13.68M | |||
Net Income (TTM) | -13.83M | |||
Net Income Avl. to Common (TTM) | -13.83M | |||
Total Revenue Growth (Q YOY) | -27.88% | |||
Earnings Growth (Q YOY) | 62.43% | |||
EPS Diluted (TTM) | -2.28 | |||
EPS Diluted Growth (Q YOY) | 73.98% | |||
Balance Sheet | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 2.80M | |||
Cash Per Share (Q) | $0.44 | |||
Total Current Assets (Q) | 3.43M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 4.50M | |||
Current Ratio (Q) | 2.857 | |||
Book Value Per Share (Q) | $0.71 | |||
Total Assets (Q) | 6.23M | |||
Total Current Liabilities (Q) | 1.20M | |||
Total Debt (Q) | 708.00K | |||
Total Liabilities (Q) | 1.73M | |||
Total Common Equity (Q) | 4.50M | |||
Cash Flow | VYNT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 3.75M | |||
Cash from Financing (TTM) | 305.00K | |||
Net Change in Cash (TTM) | -8.91M | |||
Levered Free Cash Flow (TTM) | -9.42M | |||
Cash from Operations (TTM) | -12.96M | |||